Briacell Therapeutics Corp

BCTX

4.180USD

+0.010+0.24%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Briacell Therapeutics Corp's Score

Industry at a Glance

Industry Ranking

152 / 392

Overall Ranking

297 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Briacell Therapeutics Corp Highlights

StrengthsRisks

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -0.12, at a high 3-year percentile range.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.82.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

40.000

Target Price

+199.85%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Briacell Therapeutics Corp is 7.21, ranking 141 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.21

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.45

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.50

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.10

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Briacell Therapeutics Corp is 7.06, ranking 179 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.12, which is -27726600.41% below the recent high of 34214.50 and -83268.72% above the recent low of -102.88.

Score

Industry at a Glance

Previous score

7.06

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 152/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Briacell Therapeutics Corp is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 40.00, with a high of 40.00 and a low of 40.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Briacell Therapeutics Corp is 5.93, ranking 287 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 9.50 and the support level at 1.45, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.95

Change

-0.02

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Iroquois Capital Management, LLC

57.20K

+2.14%

L5 Capital Inc.

17.40K

+2.65%

3I Management LLC

9.17K

-75.15%

Plambeck (Jeremy Myung Jae)

1.63K

--

Williams (William V)

1.13K

-96.81%

Desjardins Securities Inc.

905.00

+158.57%

Bondarenko (Jamieson)

799.00

-25.81%

UBS Financial Services, Inc.

64.00

-95.80%

Embro-Pantalony (Vaughn C)

163.00

+36.97%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Briacell Therapeutics Corp. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 2.02. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Briacell Therapeutics Corp

BCTX

5.95 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment